Clene Inc. (CLNN)
- GlobeNewswire
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
First patient, first visit is planned for early June 2024Enrollment has been expanded by 80% to a maximum of 180 participants‘Real-world’ drug efficacy data will be collected by monitoring potential drug effects on survival and disease progression, as well as safety SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improvin
- GlobeNewswire
Clene to Present at Upcoming May Conferences
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, today announced that it will participate in the following investor conferences in May. Mizuho Neuroscienc
- Simply Wall St.
Clene First Quarter 2024 Earnings: Misses Expectations
Clene ( NASDAQ:CLNN ) First Quarter 2024 Results Key Financial Results Net loss: US$11.1m (loss narrowed by 5.9% from...
